Copied
 
 
2022, DKK
29.09.2023
Bruttoresultat

1.005''

Primær drift

659''

Årets resultat

470''

Aktiver

13.684''

Kortfristede aktiver

3.410''

Egenkapital

4.549''

Afkastningsgrad

5 %

Soliditetsgrad

33 %

Likviditetsgrad

39 %

Resultat
29.09.2023
Årsrapport
2022
29.09.2023
2021
04.10.2022
2020
03.09.2021
2019
06.11.2020
2018
29.05.2019
2017
30.05.2018
2016
02.06.2017
2015
25.05.2016
Nettoomsætning3.450.897.0003.068.983.0002.727.431.0002.039.469.0001.417.166.0001.417.224.0001.275.316.0001.160.163.000
Bruttoresultat1.004.857.000583.823.000494.437.00065.121.000214.188.000241.078.000228.344.0000
Resultat af primær drift659.432.000287.803.000217.998.000-237.004.000317.583.000168.950.000152.955.00045.576
Indtægter af kapitalandele (tilknyttede og associerede) 00000000
Finansielle indtægter130.396.00050.045.00027.503.00028.214.0007.879.00033.348.000193.00063.539.000
Finansieringsomkostninger-188.206.000-65.944.000-112.750.000-17.242.000-3.426.000-4.426.000-13.715.000-26.391.000
Andre finansielle omkostninger00000000
Resultat før skat601.622.000271.904.000132.751.000-226.032.000322.036.000197.872.000139.433.000-186.480.000
Resultat470.320.000213.460.000103.550.000-176.316.000253.501.000170.735.000109.185.000-124.280.000
Forslag til udbytte00000000
Aktiver
29.09.2023
Årsrapport
2022
29.09.2023
2021
04.10.2022
2020
03.09.2021
2019
06.11.2020
2018
29.05.2019
2017
30.05.2018
2016
02.06.2017
2015
25.05.2016
Kortfristede varebeholdninger1.129.820.000639.023.000473.196.000409.082.0000000
Kortfristede tilgodehavender fra salg og tjenesteydelser 2.140.409.0001.449.501.000913.984.000949.908.000590.805.000469.919.000634.829.000203.796.000
Likvider140.262.00045.031.000331.911.00049.456.000178.945.0004.775.00021.160.00011.092.000
Kortfristede aktiver3.410.491.0002.133.555.0001.719.091.0001.408.446.000769.750.000474.694.000655.989.000214.888.000
Immaterielle aktiver og goodwill349.543.000400.019.000514.013.000640.657.00010.524.0009.917.00012.798.0008.645.000
Finansielle anlægsaktiver00000000
Materielle aktiver9.923.626.0005.922.048.0003.615.323.0003.459.027.0003.760.327.0003.931.767.0004.062.007.0004.167.554.000
Langfristede aktiver10.273.169.0006.322.067.0004.129.336.0004.099.684.0003.770.851.0003.941.684.0004.074.805.0004.176.199.000
Aktiver13.683.660.0008.455.622.0005.848.427.0005.508.130.0004.540.601.0004.416.378.0004.730.794.0004.391.087.000
Aktiver
29.09.2023
Passiver
29.09.2023
Årsrapport
2022
29.09.2023
2021
04.10.2022
2020
03.09.2021
2019
06.11.2020
2018
29.05.2019
2017
30.05.2018
2016
02.06.2017
2015
25.05.2016
Forslag til udbytte00000000
Egenkapital4.549.198.0004.078.878.0003.865.418.0003.761.868.0003.938.184.0003.684.683.0003.598.246.0003.489.060.000
Hensatte forpligtelser255.342.000237.339.000202.946.000181.871.000236.083.000199.579.000163.034.000129.754.000
Langfristet gæld til banker00000000
Anden langfristet gæld00000000
Leverandører af varer og tjenesteydelser1.820.935.0001.246.214.000409.387.000280.920.00080.778.00081.725.000104.398.000148.710.000
Kortfristede forpligtelser8.741.455.0002.424.146.0001.643.359.0001.564.391.000366.334.000532.116.000969.514.000772.273.000
Gældsforpligtelser8.879.120.0004.139.405.0001.780.063.0001.564.391.000366.334.000532.116.000969.514.000772.273.000
Forpligtelser8.879.120.0004.139.405.0001.780.063.0001.564.391.000366.334.000532.116.000969.514.000772.273.000
Passiver13.683.660.0008.455.622.0005.848.427.0005.508.130.0004.540.601.0004.416.378.0004.730.794.0004.391.087.000
Passiver
29.09.2023
Nøgletal
29.09.2023
Årsrapport
2022
29.09.2023
2021
04.10.2022
2020
03.09.2021
2019
06.11.2020
2018
29.05.2019
2017
30.05.2018
2016
02.06.2017
2015
25.05.2016
Afkastningsgrad 4,8 %3,4 %3,7 %-4,3 %7,0 %3,8 %3,2 %0,0 %
Dækningsgrad 29,1 %19,0 %18,1 %3,2 %15,1 %17,0 %17,9 %Na.
Resultatgrad 13,6 %7,0 %3,8 %-8,6 %17,9 %12,0 %8,6 %-10,7 %
Varelagerets omsætningshastighed 3,1 4,8 5,8 5,0 Na.Na.Na.Na.
Egenkapitals-forretning 10,3 %5,2 %2,7 %-4,7 %6,4 %4,6 %3,0 %-3,6 %
Payout-ratio Na.Na.Na.Na.Na.Na.Na.Na.
Gældsdæknings-nøgletal 350,4 %436,4 %193,3 %-1.374,6 %9.269,8 %3.817,2 %1.115,2 %0,2 %
Soliditestgrad 33,2 %48,2 %66,1 %68,3 %86,7 %83,4 %76,1 %79,5 %
Likviditetsgrad 39,0 %88,0 %104,6 %90,0 %210,1 %89,2 %67,7 %27,8 %
Resultat
29.09.2023
Gæld
29.09.2023
Årsrapport
29.09.2023
Nyeste:01.04.2022- 31.03.2023(offentliggjort: 29.09.2023)
Information om virksomhedens regnskabsklasse:The annual report of FUJIFILM Diosynth Biotechnologies Denmark ApS for 2021/22 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to large reporting class C entities.
Beretning
29.09.2023
Dato for ledelsens godkendelse af årsrapporten:2023-09-28
Statement by Management on the annual report
Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of FUJIFILM Diosynth Biotechnologies Denmark ApS for the financial year 1 April 2022 - 31 March 2023.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:We are honored to be part of Fujifilm's relentless pursuit for innovation in life sciences, building new facilities and leading the future of biomanufacturing through innovation and sustainability. The latest expansion fueled by ongoing recent investment of DKK 11 billion will transform our site into the largest end-to-end CDMO in Europe. Message from Executive Management Fiscal Year 2022/2023 was a very successful year for our company. It was the third full financial year for us under the ownership of FUJIFILM Corporation and as part of FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization for biologics, vaccines and advanced therapies. For the Fiscal Year ending 31 March 2023, we recorded DKK 3,450. 9 million in revenue and DKK 601. 6 million in profit before tax. Expansion projects have been in focus during this time. We are committed to completing and getting the first expansion ready for operations. Once ready the facility will expand production lines for bulk drug substance with six additional mammalian cell bioreactors. We also held a ground-breaking ceremony in September of 2022 to celebrate the start of our second growth project to transform the Denmark site into the largest end-to-end CDMO in Europe. The expansion will increase the capacity of the current site by adding 8 x 20,000 L bioreactors and two downstream processing lines. When the expansion is completed, the site will offer 20 x 20,000 L bioreactors for drug substance production complemented by comprehensive drug product and finished goods services. The expansion project will create 450 new jobs in Denmark and is expected to be completed in the Summer of 2026. Close collaboration with our sister site in North Carolina (USA) has been at the center of our attention throughout the year, as we are dedicated to building a strong organization across the two sites enabling us to scale production volumes and support the needs of our partners. The continued development of our capacity across sites enables us to support our partners in manufacturing lifesaving therapies for patients around the world and to deliver on our promise to them for support from pre-clinical through to commercialization. Complementing our commercial support is the establishment of our drug product manufacturing filling line which by 2024 will complete our end-to-end services portfolio, making it even more attractive for clients to partner with us. Financial model FDBD is a subsidiary of FUJIFILM Corporation. Our business FUJIFILM Diosynth Biotechnologies Denmark (FDBD) is a part of FUJIFILM Diosynth Biotechnologies (FDB), a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines and advanced therapies. FDB offers complete solutions in pharmaceutical manufacturing – from pre-clinical investigations and process development to commercial cGMP production. The focus is to combine technical leadership in cell culture, microbial fermentation, cell and gene therapies with world class cGMP manufacturing facilities to advance tomorrow’s medicines. FDB have major locations in the Unites States of America, the United Kingdom and Denmark and it is building a new manufacturing site in Holly Springs, North Carolina, USA. FDBD's purpose, along with the FDB group, is to be the leading and most trusted global contract development and manufacturing organization partner in the biopharmaceutical industry. Business area Drug Substance Manufacturing Our large-scale drug substance manufacturing facility has a current capacity of 120,000 liters to reliably manufacture biopharmaceuticals for late phase and commercial use. Business area Assembly, Label and Pack Our facility for assembly, label and pack manufactures advanced delivery systems and ensures required labelling and secure packaging of the therapies for patients worldwide. The site also houses quality control laboratories, warehouses, and a number of organizations, supporting manufacturing activities: process science, supply chain management, engineering and quality assurance